Infertility and ART

Friday, December 9, 2011


08:30-10:00
OPENING SESSION
Chairpersons J.H.Lang, China (Honorary Chairman)
C.Q. Zhou, China
G. Lu, China
Z.J. Chen, China
Z. Ben Rafael, Israel
08:30-08:35 Opening remarks
Experts views on where our field is heading
08:35-08:55 Stem Cells and Their Significance in Gynecology
C. De Geyter, Switzerland
08:55-09:15 Sperm fitness testing and experimental IVF on integrated Lab-on-a-Chip devices
J. Cheng, K. Mitchelson, China
09:15-10:00
WHEN WILL LAPAROSCOPY REPLACE ALMOST ALL LAPAROTOMIES?
Capsule Video-Laparoscopy is developing fast, covering an ever growing number of operations and disciplines. Prof. Nezhat, often referred to as a "Wizard" in Laparoscopy, will present his personal view, an odyssey of science technology and will explain where Video-Laparoscopy is heading and if this technology will ever put to rest all laparotomies, and in his words: "The objectives of the lecture are, to motivate the younger physicians, bring hope to their work and education and encouragement in their careers"
C.R. Nezhat, USA

10:00-10:20 Coffee break

10:20-11:50
MILD STIMULATION FOR IVF
Capsule Proponents of monofollicular stimulation claim that this is the way for IVF, especially in an era of single embryo transfer (SET). Opponents, in turn, suggest that pregnancy rates are too low to make it a viable alternative. Can we agree on what direction we should take?
Chairpersons S.A. Carson, USA
Z.J. Chen, China
10:20-11:05
Debate: Should We Always Strive to Use Mild Stimulation for IVF?
Proposition: Mild stimulation IVF combined with single embryo transfer (SET) should be the method used for IVF
S. Daya, Canada
Opposition: Results are too low and dropout rates are too high to make it a viable option!
N. Gleicher, USA
Discussion
11:05-11:50
Debate: Preventing all Multiple Pregnancies by Systematic Single Embryo Transfer (SET) for all?
Yes: G.N. Huang, China
No: N. Gleicher, USA
Discussion
Objectives To acquire knowledge about the following:
    What is "mild" stimulation and what are its advantages and disadvantages
  • Which patients are the most likely candidates for such stimulation
  • Arguments for and against SET
  • SET utilization in different parts of the world and related government regulations
  • Why transfer of more than one embryo remains popular amongst patients and physicians

11:50-12:10 Poster viewing

12:10-13:40
PREIMPLANTATION GENETIC SCREENING (PGS): WHAT IS NEXT?
Supported by unrestricted grant from IBSA
Capsule Preimplantation genetic diagnosis (PGD) was initially introduced to identify single gene defects, but evolved under the acronym "PGS" (preimplantation genetic screening) into a tool to detect embryo aneuploidy. The proposed goal was to improve pregnancy rates in IVF, and reduce spontaneous abortion rates, Thus far, studies indicate that in order to compensate for the risks involved, improvement of more than 10% is needed. The current question is does the future of PGS lie in the technical improvements? Can we keep refining the method, using newer technologies such as comparative genomic hybridization (CGH), and embryo diagnosis via trophectoderm biopsy?
Chairpersons S. Daya, Canada
M. von Wolff, Switzerland (TBC)
C. De Geyter, Switzerland (TBC)
12:10-12:55
Debate: PGS is an Experimental Tool that Should be Banned from Routine Clinical Use!
Proposition: PGS, as currently practiced, is associated with inferior results and should not be routinely offered
N. Gleicher, USA
Opposition: The beneficial effects of preimplantation genetic diagnosis for aneuploidy support extensive clinical applications
Guangxiu Lu, China (TBC)
12:55-13:15 Can CGH in PGS be the answer for the inefficiencies in PGS?
K.W.R. Choy, Hong Kong
13:15-13:40 Meiotic contribution to aneuploidy
Y.W. Xu, China
Objectives Upon completion of this debate, the audience will learn:
  • The hypothesis that makes PGS an attractive proposition
  • Reasons why PGS, as performed, failed to meet expectations
  • New technologies and techniques, which, potentially, may positively affect PGS results
  • What the IVF field can learn from the PGS experience
  • About CGH and its role in future PGS

13:40-14:30 Lunch break

14:30-16:00
IN VITRO MATURATION (IVM)
Supported by unrestricted grant from IBSA
Capsule IVM is becoming more effective,but will it ever replace IVF? Benefits, risks and pitfalls of the procedure
Chairpersons C. De Gytner, Switzerland
Hefeng Huang, China
14:30-15:15
Debate: Will IVM Ever Replace Standard IVF?
Yes: Results of IVM are comparable to standard IVF with or without stimulation
M. Benkhalifa, France
No: IVM does not offer any advantage over current IVF practice
X. Liang, China
Discussion
15:15-15:40 IVM for PCOS patients
M. Benkhalifa, France
15:40-16:00 What have we learned from oocyte donation programs!
O. Coll, Spain
Objectives Upon completion of this session, the audience will have acquired:
  • Understanding of the place of IVM in comparison to IVF
  • Understanding of the laboratory procedures
  • Special indications for IVM
  • IVM for PCOS
  • PCOS as egg donors

16:00-16:30 Coffee break

16:30-18:00
IMPROVING RESULTS IN IVF
Capsule Improving the results of IVF requires that each aspect of the treatment from the clinical elements of ovarian stimulation, to laboratory work and quality assurance, to awareness of infection and risk, stimulation and embryo transfer techniques be boosted. Disagreement exists only over basic procedures and also over the universal use of ICS
Chairpersons O. Coll, Spain
C.Q. Zhou, China
Z.J. Chen, China
16:30-16:55 Quality Management in IVF
B. Imthurn, Switzerland
16:55-17:15 The standardization and safety of ART
G.X. Lu, China
17:15-17:40 Impact of viral infection on reproductive function
O. Coll, Spain
17:40-18:00 Is ICSI overused?
J. Liu, China
Objectives: Upon completion of this session, the audience will have learned:
  • QA and QC in the lab wok
  • Effect of infection on the results
  • Are we abusing ICSI?
18:30-19:45 Special entertaining performance of “Snakes, Bugs and Us”
By “Skip” Granai, MD, USA



Saturday, December 10, 2011


08:30-10:00
ASSESSMENT AND TREATMENT OF OVARIAN RESERVE
Capsule Diminished ovarian reserve (DOR) remains a common, frustrating and Under diagnosed condition. Lack of criteria for diagnosis makes it difficult to assess and compare prevalence of diagnosis and results of treatments.Questions have been raised as to whether DOR even lends itself to treatment and, if so, whether treatment regimen results differ
Chairpersons S. Carson, USA
C. De Gytner, Switzerland
M. Benkhalifa, France
08:30-08:55
Has Anti-Müllerian Hormone (AMH) Become Essential in Assessing Ovarian Reserve?
S. Daya, Canada
08:55-09:40
Debate: Can Diminished Ovarian Reserve be Treated Effectively?
Yes: N. Gleicher, USA
No: S. Daya, Canada
Discussion
09:40-10:00 2000 IU of hCG in responders does not affect the outcome of IVF
Y. Kuang, China
Objectives Upon completion of these debates, the audience will have learned the following:
  • How DOR is defined in the literature
  • Why age-specific ovarian reserve determination improves sensitivity of diagnosis of DOR
  • What the best methodologies are for diagnosing DOR
  • Whether DOR lends itself to treatment

10:00-10:20 Coffee break

10:20-11:50
POLYCYSTIC OVARIAN SYNDROME (PCOS) AND OHSS
Capsule Controversy over the management of Polycystic Ovarian Syndrome (PCOS) patients continues. These patients tend to have ovarian hyperstimulation syndrome (OHSS) and multiple pregnancies when stimulated. The debate here is what should be the first step of treatment? Should we start with stimulation +IUI which can’t prevent multiples or should we persue surgical techniques that can provide temporary relief and success, albeit at a possible price, or should we just proceed with IVF?
Chairpersons E. Manalo, Philippines
S. Daya, Canada
H.F. Huang, China
10:20-11:05
Debate: Treating Anovulatory PCOS Patients: What Should be the First Choice?
Gonodotropins versus clomiphene citrate as first line therapy to improve pregnancy rate 
S. Daya, Canada
Ovulation induction +IUI and IVF
N. Gleicher, USA
Discussion
PCOS in Filipino women
E. Manalo, Philippines
11:30-11:50 Do PCOS patients have delayed ovarian aging?
Z. Ben Rafael, Israel
Objectives To acquire knowledge about the following:
  • The most effective primary treatment for PCOS
  • Advantages and limitations of treatment options

11:50-12:10 Poster viewing

12:10-13:40
HOT CONTROVERSIES ON ART CLINICAL ISSUES
Moderators Z. Ben Rafael, Israel
C.Q. Zhou, China
Discussants Z.J. Chen, China
S. Daya, Canada
N. Gleicher, USA
S. Carson, USA
M. Benkhalifa, France
Round Table Discussion and Expert Opinions on:
  1. Should tests of ovarian reserve be routinely done
  2. Low dose or high dose: Which are the prefered responders
  3. Protocols for IVF in patients with endometriosis
  4. Strategies to prevent OHSS
  5. Cheaper IVF: How can it be achieved?
  6. Alternative medicine for IVF: Is it over-rated? Merely a placebo effect?
  7. Difficult ET, what is the next step?
  8. Assisted zona hatching: Should it be continued?
  9. Luteal support in IVF: PO? PV? IM? For how long
  10. Should PGD be routine in patients with recurrent miscarriages?

13:40-14:30 Lunch break

14:30-16:00
BASIC ASPECTS OF ART
Chairpersons X.C. Yu, China
J. Zhang, China
S.A. Carson
, USA
14:30-14:55 Multipotent adult germ line stem cells: New therapeutic hope?
R. Schwartz, USA
14:55-15:15 Genetic imprinting and embryonic development
H.F. Huang, China
15:15-15:40 The value of sperm morphology
Z.W. Chen, China
15:40-16:00 Embryonic stem cell therapeutic potential: Is the future here?
Y.L. Ma, China

16:00-16:30 Coffee break

16:30-18:00
ONCOFERTILITY: THE PRESERVATION OF FUTURE GENERATIONS
Capsule About 75% of children treated for cancer are expected to be long term survivors, and hence fertility preservation is one of the aims of the treatment that also allows for normal life experience. The multiple modalities of treatment which include modified surgery, alternative modalities of chemotherapies, can help preserve fertility. Newer techniques, even if still experimental like gamete freezing, in vitro maturation (IVM) and IVF, expand the choices. Fertility saving surgery can be performed in certain cancer cases, however no clear guidelines or limit are set, and the age in which these procedures should be offered is controversial
Chairpersons Z.J. Chen, China
M. von Wolff, Switzerland
O. Coll, Spain
16:30-17:00 Should fertility be saved in the infants and adolescence with malignancies?
S. Carson, USA
17:00-17:30 Should fertility be spared in women with ovarian malignancies?
S. Granai, USA
17:30-17:00 Prophylactic surgery in BRCA gene patients: What should be done and when?
R. Moore, USA



Sunday, December 11, 2011


08:30-10:00
Rescue ICSI
Capsule Is rescue ICSI is effective if fertilization -failure after conventional IVF? Some say yes , the most important thing is to choose the rif it is done early enough, within the “rescue window” before oocyte aging
Chairperson C. Zhou, China
Debate:
Is Early application of rescue ICSI (3-8 hours after insemination) effective in conventional IVF?
08:30-08:45 Yes, provided hat it is done early enough before oocytes aging it can be used often
H. Sun, China
08:45-09:00 No, it should be used restrictively
Y. Huang, China
09:00-09:15 Yes again! It should be performed with reservation
G. Huang, China
Debate:
Lutesl phase support? Is it really needed?
09:25-09:40 Proposition: There is no clear evidence show luteal phase support is necessary in routing ART
G. Zhu, China
09:40-09:55 Oposition: luteal phase support is important in IVF
C. Zhou, China
Discussion

10:00-10:20 Coffee break

10:20-11:50
ENDOMETRIOSIS: WHAT IS THE BEST TREATMENT FOR INFERTILE PATIENTS?
Capsule Can we choose from the many therapeutic options available for this poorly understood condition?
Chairpersons Y.H. Huang, China 
M. Benkhalifa, France
S. Daya, Canada
10:20-11:05
Debate: Endometriosis - surgery or IVF?
IVF first
Jinghe Lang, China
Surgery first
G.A. Chen, China
Discussion
11:05-11:30 Role of laparoscopic treatment of endometriosis in patients with failed IVF
Y.Q. Yao, China
11:30-11:50 What should be done with recurrent endometriosis in fertille patients?
S.H. Yao, China